In a post on the Oxford University Press blog, Dr. Bruce Miller discusses the potential impact that a treatment for dementia could have on our economy. Delaying the onset of symptoms for just five years could save billions of dollars. These dollars could then be invested in providing services to improve the quality of life of patients and caregivers and to fund more research to find a cure.
Tag Archives: clinical trial
As trialists are retooling in the face of disappointing results in Alzheimer’s disease (AD), researchers in frontotemporal degeneration (FTD) are learning from AD woes and gearing up to take a seat in the front row. This year’s 4th International Conference on Clinical Trials in Alzheimer’s Disease, (CTAD), held 3-5 November 2011 in San Diego, California, included a session on preparing for treatment trials in FTD. Presenters made the case that trials in FTD may stand a better chance of succeeding than those in AD. As research has uncovered many molecular pathways common to FTD and related disorders ranging from the common (AD) to the rare amyotrophic lateral sclerosis (ALS), any treatments developed for FTD may have broad applications and energize the field of neurodegeneration as a whole. Read more
A new clinical trial for people with progressive supranuclear palsy may open the door for other treatments
Progressive supranuclear palsy (PSP) is a degenerative brain disease leading to difficulties with walking and balance, problems with eye movements, changes in behavior and executive control, difficulty with speech and swallowing, and dementia. PSP, corticobasal degeneration (CBD) and some of the frontotemporal dementias (FTD) are tauopathies—diseases associated with the abnormal accumulation of the protein tau. It is likely that whether one presents with PSP, CBD or FTD depends in part on the location in the brain of these microscopic changes, although individual differences may play an important role as well. Read more